A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma

Rivista
Future Oncology
Autori
Dreyling M, Tam CS, Wang M, Smith SD, Ladetto M, Huang H, Novotny W, Co M, Romano A, Holmgren E, Huang J, Gouill SL
Citazione bibliografica
2021 Jan;17(3):255-262
DOI
10.2217/fon-2020-0794
Unit di ricerca
Fase I